Primary mediastinal B-cell lymphoma (PMBCL) is a rare and aggressive type of non-Hodgkin’s lymphoma that originates in the white blood cells behind the breastbone. Although the cause of PMBCL is ...
AbbVie (ABBV) and Genmab (GMAB) announced that their jointly developed bispecific antibody epcoritamab, marketed as Epkinly ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
Challenges Remaining for Yttrium-90 Radioembolization: The Case for Standardized Dosimetry and Comparative Local Control Analyses in Liver Tumors As of September 2, 2024, 129 patients with LBCL (HGBCL ...
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain. We ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 ...
A drug co-developed by Genmab and AbbVie to treat a certain type of lymphoma failed to meet its primary endpoint in a Phase 3 trial. The companies on Thursday clarified that the trial's sole U.S.
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study Mosun-Pola ...
Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results